Founded in 2013, Renovion leverages a groundbreaking pharmaceutical discovery from the University of North Carolina-Chapel Hill to combat chronic inflammatory airway diseases. Their flagship product, Arina-1, is currently in the pre-clinical stage. Renovion's advanced therapy aims to treat patients with chronic inflammatory airway diseases, including those who have undergone a bilateral lung transplant, by addressing infection and reducing airway inflammation. This innovative approach offers potential treatment options for conditions such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD), ultimately improving patients' quality of life.